Skip to main content
ABT
NYSE Life Sciences

Abbott 10-Q: Q3 GAAP EPS $0.53 as Exact Sciences Amortization and $1.05B Legal Charges Hit Earnings

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$115.48
Mkt Cap
$199.877B
52W Low
$81.97
52W High
$132.025
52W Position info
41% above low
Off High info
13% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

ABT sits 41% above its 52-week low of $81.97.

Summary

Abbott's Q3 10-Q confirms $13.0B of sales (+14.5%) but GAAP EPS of just $0.53, weighed down by $841M of intangible amortization from Exact Sciences and $1.05B of infant-formula legal settlements. The filing also details the planned tax-free spinoff of the Nutrition business, targeted to close by the end of 2027.


Key Events · Earnings and Guidance · ABT

  • Q3 Sales Up 14.5%, GAAP EPS Halved

    Net sales were $13,013M versus $11,369M a year ago, but net earnings fell to $920M and diluted EPS to $0.53 from $0.94, as amortization of intangibles rose to $841M from $420M.

  • Legal Charges Total $1.05B

    The quarter carried a $670M charge to resolve the Gill case and NEC claims for about 2,000 additional infants, plus a $385M payment settling the DOJ qui tam matter.

  • Exact Sciences Deal Reshapes Balance Sheet

    The $20.6B acquisition was funded with $20.0B of new long-term debt; long-term debt rose to $29,451M from $9,896M and cash fell to $4,052M from $8,522M, pushing quarterly net interest expense to $297M from $44M.

  • Purchase Accounting Adjusted Upward

    A $3.2B increase in acquired intangible assets with a matching goodwill reduction added roughly $100M of amortization in the quarter; the allocation remains preliminary and could change materially.


Analysis · ABT · Life Sciences

The headline numbers were pre-released on October 21, but the full 10-Q shows how much of the profit decline is accounting rather than operating. Sales rose 14.5% to $13.0B, yet GAAP net earnings fell to $920M ($0.53 per diluted share) from $1,644M, because amortization of intangibles jumped to $841M from $420M after the Exact Sciences deal and SG&A absorbed $1.05B of legal settlements ($670M NEC/Gill, $385M DOJ). Operating earnings still grew at the segment level to $3,420M from $2,980M, so the shortfall sits below the operating line. The balance sheet is the other story: cash fell to $4.1B from $8.5B and long-term debt rose to $29.5B from $9.9B to fund the $20.6B acquisition, lifting net interest expense to $297M from $44M. Abbott also put mechanics on the Nutrition separation — a tax-free share distribution to holders targeted for completion by the end of 2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ABT was trading at $115.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $199.9B. The 52-week trading range was $81.97 to $132.03. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ABT - Latest Insights

ABT
Oct 21, 2026, 8:53 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $98.21
Real-time Price: $104.02 info
Change: +$5.81 (+6%) info
Market Cap: $179.897B info
ABT
Oct 21, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $99.52
Real-time Price: $104.02 info
Change: +$4.50 (+5%) info
Market Cap: $179.897B info
ABT
Oct 21, 2026, 7:32 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $100.55
Real-time Price: $104.02 info
Change: +$3.47 (+3%) info
Market Cap: $179.897B info
ABT
Oct 21, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $100.52
Real-time Price: $104.02 info
Change: +$3.50 (+3%) info
Market Cap: $179.897B info
ABT
Oct 05, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $97.53
Real-time Price: $104.02 info
Change: +$6.49 (+7%) info
Market Cap: $179.897B info